参考文献/References:
[1] Connelly MA,Otvos JD,Shalaurova I,et al. GlycA,a novel biomarker of systemic inflammation and cardiovascular disease risk[J]. J Transl Med,2017,15(1):219.
[2] Mehta NN,Dey AK,Maddineni R,et al. GlycA measured by NMR spectroscopy is associated with disease activity and cardiovascular disease risk in chronic inflammatory diseases[J]. Am J Prev Cardiol, 2020 ,4:100120.
[3] Fung E,Chan EYS,Ng KH,et al. Towards clinical application of GlycA and GlycB for early detection of inflammation associated with (pre)diabetes and cardiovascular disease:recent evidence and updates[J]. J Inflamm(Lond),2023,20(1):32.
[4] Joshi AA,Lerman JB,Aberra TM,et al. GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis[J]. Circ Res,2016,119(11):1242-1253.
[5] Otvos JD,Shalaurova I,Wolak-Dinsmore J,et al. GlycA:a composite nuclear magnetic resonance biomarker of systemic inflammation[J]. Clin Chem,2015,61(5):714-723.
[6] Bell JD,Brown JC,Nicholson JK,et al. Assignment of resonances for ‘acute-phase’ glycoproteins in high resolution proton NMR spectra of human blood plasma[J]. FEBS Lett,1987,215(2):311-315.
[7] Gabay C,Kushner I. Acute-phase proteins and other systemic responses to inflammation[J]. N Engl J Med,1999,340(6):448-454.
[8] Crook AA,Powers R. Quantitative NMR-based biomedical metabolomics:current status and applications[J]. Molecules,2020,25(21):5128.
[9] Noel M,Chasman DI,Mora S,et al. The inflammation biomarker GlycA reflects plasma N-glycan branching[J]. Clin Chem,2023,69(1):80-87.
[10] McGee AC,Reinicke T,Carrasco D,et al. Glycoprotein acetyls associate with intraglomerular hemodynamic dysfunction,albuminuria,central adiposity,and insulin resistance in youth with type 1 diabetes[J]. Can J Diabetes,2024,48(4):244-249.e1.
[11] Ohyama Y,Yamaguchi H,Ogata S,et al. Racial heterogeneity of IgA1 hinge-region glycoforms in patients with IgA nephropathy[J]. iScience,2022,25(11):105223.
[12] Crick DCP,Khandaker GM,Halligan SL,et al. Comparison of the stability of glycoprotein acetyls and high sensitivity C-reactive protein as markers of chronic inflammation[J]. Immunology,2024,171(4):497-512.
[13] Riggs KA,Joshi PH,Khera A,et al. GlycA,hsCRP differentially associated with MI,ischemic stroke:in the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis:GlycA,hsCRP differentially associated MI,stroke[J]. Am J Prev Cardiol,2022,12:100373.
[14] Ferro F,Spelat R,Pandit A,et al. Glycosylation of blood cells during the onset and progression of atherosclerosis and myocardial infarction[J]. Trends Mol Med,2024,30(2):178-196.
[15] Jang S,Ogunmoroti O,Ndumele CE,et al. Association of the novel inflammatory marker GlycA and incident heart failure and its subtypes of preserved and reduced ejection fraction:the Multi-Ethnic Study of Atherosclerosis[J]. Circ Heart Fail,2020,13(8):e007067.
[16] Kasher M,Freidin MB,Williams FMK,et al. Glycoprotein acetyls is a novel biomarker predicting cardiovascular complications in rheumatoid arthritis[J]. Int J Mol Sci,2024,25(11):5981.
[17] Lateef SS,Al Najafi M,Dey AK,et al. Relationship between chronic stress-related neural activity,physiological dysregulation and coronary artery disease in psoriasis:findings from a longitudinal observational cohort study[J]. Atherosclerosis,2020,310:37-44.
[18] McGarrah RW,Kelly JP,Craig DM,et al. A novel protein glycan-derived inflammation biomarker independently predicts cardiovascular disease and modifies the association of HDL subclasses with mortality[J]. Clin Chem,2017,63(1):288-296.
[19] Levine JA,Han JM,Wolska A,et al. Associations of GlycA and high-sensitivity C-reactive protein with measures of lipolysis in adults with obesity[J]. J Clin Lipidol,2020,14(5):667-674.
[20] Radford-Smith DE,Patel PJ,Irvine KM,et al. Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism[J]. PLoS One,2022,17(1):e0261555.
[21] Vicente MM,Leite-Gomes E,Pinho SS. Glycome dynamics in T and B cell development:basic immunological mechanisms and clinical applications[J]. Trends Immunol,2023,44(8):585-597.
[22] Monahan RC,Li-Gao R,Noordam R,et al. Glycoprotein acetyls response to a mixed meal is associated with increased insulin resistance and risk of type 2 diabetes in a middle-aged population[J]. Clin Nutr ESPEN,2025,66:523-529.
[23] Richardson TG,Leyden GM,Wang Q,et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation[J]. PLoS Biol,2022,20(2):e3001547.
[24] Connelly MA,Gruppen EG,Wolak-Dinsmore J,et al. GlycA,a marker of acute phase glycoproteins,and the risk of incident type 2 diabetes mellitus:PREVEND study[J]. Clin Chem Acta,2016,452:10-17.
[25] Muhlestein JB,May HT,Galenko O,et al. GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography:the intermountain heart collaborative study[J]. Am Heart J,2018,202:27-32.
[26] Kettunen J,Ritchie SC,Anufrieva O,et al. Biomarker glycoprotein acetyls is associated with the risk of a wide spectrum of incident diseases and stratifies mortality risk in angiography patients[J]. Circ Genom Precis Med,2018,11(11):e002234.
[27] Lawler PR,Akinkuolie AO,Chandler PD,et al. Circulating N-linked glycoprotein acetyls and longitudinal mortality risk[J]. Circ Res,2016,118(7):1106-1115.
[28] Jang S,Ogunmoroti O,Zhao D,et al. The association of novel inflammatory marker GlycA and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis(MESA)[J]. PLoS One,2021,16(3):e0248644.
[29] Filho RCF,Generoso G,Cardoso R,et al. GlycA levels independently predict coronary artery calcium incidence and progression in the ELSA-Brasil Cohort(Brazilian Longitudinal Study of Adult Health)[J]. Am J Cardiol,2024,22:29-36.
[30] Fashanu OE,Oyenuga AO,Zhao D,et al. GlycA,a novel inflammatory marker and its association with peripheral arterial disease and carotid plaque:The Multi-Ethnic Study of Atherosclerosis[J]. Angiology,2019,70(8):737-746.
[31] Ormseth MJ,Chung CP,Oeser AM,et al. Utility of a novel inflammatory marker,GlycA,for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis[J]. Arthritis Res Ther,2015,17(1):117.
[32] Olson ML,Rentería-Mexía A,Connelly MA,et al. Decreased GlycA after lifestyle intervention among obese,prediabetic adolescent Latinos[J]. J Clin Lipidol,2019,13(1):186-193.
[33] Barber JL,Kraus WE,Church TS,et al. Effects of regular endurance exercise on GlycA:combined analysis of 14 exercise interventions[J]. Atherosclerosis,2018,277:1-6.
[34] Gruppen EG,Connelly MA,Otvos JD,et al. A novel protein glycan biomarker and LCAT activity in metabolic syndrome[J]. Eur J Clin Invest,2015,45(8):850-859.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(11):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(11):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(11):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(11):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(11):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]